Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

NCT02445248 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

BIOLOGICAL: Tisagenlecleucel
DRUG: Lymphodepleting chemotherapy

Sponsor

Novartis Pharmaceuticals